Brokerages predict that Voyager Therapeutics Inc (NASDAQ:VYGR) will report ($0.73) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Voyager Therapeutics’ earnings. The highest EPS estimate is ($0.48) and the lowest is ($0.92). Voyager Therapeutics reported earnings per share of ($0.57) during the same quarter last year, which would indicate a negative year over year growth rate of 28.1%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, March 21st.
On average, analysts expect that Voyager Therapeutics will report full year earnings of ($2.99) per share for the current year, with EPS estimates ranging from ($3.20) to ($2.74). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.04) per share, with EPS estimates ranging from ($4.16) to ($1.98). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Voyager Therapeutics.
A number of equities analysts have recently commented on VYGR shares. Stifel Nicolaus reissued a “buy” rating and set a $31.00 price objective (up from $20.00) on shares of Voyager Therapeutics in a research report on Monday, October 23rd. Canaccord Genuity started coverage on Voyager Therapeutics in a research report on Friday, October 27th. They set a “buy” rating and a $35.00 price objective for the company. Zacks Investment Research downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 8th. BTIG Research started coverage on Voyager Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $32.00 price objective for the company. Finally, Raymond James Financial assumed coverage on Voyager Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $35.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $26.90.
Hedge funds have recently bought and sold shares of the company. Thompson Davis & CO. Inc. boosted its holdings in shares of Voyager Therapeutics by 67.7% in the fourth quarter. Thompson Davis & CO. Inc. now owns 7,485 shares of the company’s stock valued at $124,000 after acquiring an additional 3,021 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of Voyager Therapeutics during the third quarter worth approximately $270,000. Rhumbline Advisers raised its stake in shares of Voyager Therapeutics by 34.7% during the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock worth $144,000 after purchasing an additional 4,144 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Voyager Therapeutics by 8.9% during the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after purchasing an additional 1,399 shares during the last quarter. Finally, Nationwide Fund Advisors raised its stake in shares of Voyager Therapeutics by 81.5% during the third quarter. Nationwide Fund Advisors now owns 19,779 shares of the company’s stock worth $407,000 after purchasing an additional 8,884 shares during the last quarter. 36.18% of the stock is owned by institutional investors and hedge funds.
Shares of Voyager Therapeutics (NASDAQ VYGR) traded down $0.14 during trading on Wednesday, hitting $18.93. The stock had a trading volume of 45,725 shares, compared to its average volume of 307,510. Voyager Therapeutics has a 1-year low of $8.10 and a 1-year high of $25.99. The firm has a market capitalization of $578.67, a P/E ratio of -6.61 and a beta of 4.04.
TRADEMARK VIOLATION NOTICE: This article was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/02/07/brokerages-expect-voyager-therapeutics-inc-vygr-will-post-earnings-of-0-73-per-share.html.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.